🔎 Trials Near Me

Home › Burkitt Lymphoma › Oregon

Burkitt Lymphoma clinical trials in Oregon

8 studies for Burkitt Lymphoma are looking for participants at sites in Oregon.

Cities in Oregon

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • and 1 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Oregon Health and Science University ( Site 1004), Portland
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Oregon Health & Science University, Portland
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Oregon Health and Science University - Knight Cancer Institute, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.